Skip to main content
. 2017 Jul 28;8(45):78480–78495. doi: 10.18632/oncotarget.19652

Figure 1. Expressions of HO-1, HDAC3 and P27 in diffuse large B-cell lymphoma (DLBCL).

Figure 1

(A, D) Expressions of HO-1, HDAC3 and P27 in DLBCL tissue samples were assessed at the protein level by immunohistochemistry. A representative example (ABC-DLBCL: 42; GCB-DLBCL: 8; NLD: 5) is shown (400 ×). (B, C) Expressions of HO-1, HDAC1, HDAC2, HDAC3 and P27 in different DLBCL samples and NLDs were assessed at the protein relative level by Western blot. (E) Scatter diagrams of HO-1 protein expressions in different risk groups of ABC-DLBCL patient samples by immunoreactive scores. (F) Correlation between HO-1 and P27 immunoreactive scores in ABC-DLBCL patient samples (r2=0.697; P<0.01). All experiments were repeated three times. *P<0.05, **P<0.01. Activated B-cell-like DLBCL (ABC-DLBCL), germinal-center B-cell-like DLBCL (GCB-DLBCL), normal lymph nodes (NLD).